Guidelines for follow-up in endometrial cancer
| Endometrial cancer | Clinic-based follow-up | Telephone follow-up ± blood test | PIFU |
| Low risk (<10% ROR) | If patient declines PIFU (for maximum of 2 years from end of treatment) | If patient declines PIFU (for maximum of 2 years from end of treatment) | Offer from end of treatment (after holistic needs assessment at 3 months) |
| Intermediate risk | Can be offered if patient declines PIFU for 2 years from end of treatment | Can be offered if patient declines PIFU for 2 years from end of treatment | Offer from end of treatment or after 2 years for all |
| High-intermediate risk | For 5 years (either telephone follow-up or clinic follow-up) | For 5 years (either telephone follow-up or clinic follow-up) | Offer from 2 years from end of treatment in place of telephone follow-up or clinic follow-up |
| High risk | For 5 years (either telephone follow-up or clinic follow-up) | For 5 years (either telephone follow-up or clinic follow-up) | Offer from 2 years from end of treatment in place of telephone follow-up or clinic follow-up |
PIFU, patient-initiated follow-up; ROR, risk of recurrence.